CDH1 and cancer: Recently, we demonstrated that among the four potential N-glycosylation sites of E-cadherin, Asn-554 is the selected site modified with β1,6 GlcNAc branched N-glycans resulting in deleterious effects on E-cadherin functions in cancer [21].